The globally widespread single-gene disorders β-thalassemia and sickle cell anemia (SCA) can only be cured by allogeneic hematopoietic stem cell transplantation (HSCT). HSCT treatment of thalassemia has substantially improved over the last two decades, with advancements in preventive strategies, control of transplant-related complications, and preparative regimens. A risk class-based transplant...

The germline Guanine-adenine-thymine-adenine 2 (GATA2) heterozygous mutations (GATA2 deficiency) are identified as a complex immunodeficiency, which entails susceptibility to non-tuberculous mycobacterium (NTM), fungus, or Epstein-Barr virus (EBV) infection, and hematological disorders including myelodysplastic syndrome (MDS)/acute myelogenous leukemia, accompanied by characteristic sighs such ...

Hematopoietic stem cell transplantation has been used for many years to treat various malignant and nonmalignant hematologic conditions. However, the high-dose conditioning regimen can lead to major organ dysfunction, life-threatening infection and bleeding. In the allogeneic setting, graft-versus-host disease may also develop, making post-transplant management complex. Once a transplant recipi...

It is generally accepted that acute myelogenous leukemia (AML) patients are immunocompromized. On the other hand, antileukemic immune reactivity is important for the improved survival of AML patients treated with allogeneic stem cell transplantation and antileukemic immunotherapy is also considered for patients treated with conventional chemotherapy. In this article, we review the available stu...

ABSTRACT Objectives: to assess/correlate health-related quality of life with the social dimension hematopoietic, autologous and allogeneic stem cell transplant patients in three years post-transplant. Methods: longitudinal, observational study 55 patients, a reference hospital Latin America, from September 2013 February 2019, using Quality Life Questionnaire-Core Functional Assessment Cancer Th...

Postremission therapy in patients with acute myeloid leukemia (AML) may consist of continuing chemotherapy or transplantation using either autologous or allogeneic stem cells. Patients with favorable subtypes of AML generally receive chemotherapeutic consolidation, although recent studies have also suggested favorable outcome after hematopoietic stem cell transplantation (HSCT). Although alloge...

Acute myeloid leukemia (AML) refers leukemias that arise from a myeloid precursor in the bone marrow. There is a high incidence of relapse, which has prompted research into various postremission strategies using either allogeneic (allo) or autologous hematopoietic stem cell transplantation (HSCT). HSCT refers to a procedure that infuses hematopoietic stem cells i to restore bone marrow function...

Acute myeloid leukemia (AML) refers to a set of leukemias that arise from a myeloid precursor in the bone marrow. There is a high incidence of relapse, which has prompted research into a variety of postremission strategies using either allogeneic or autologous hematopoietic stem cell transplantation (HSCT). HSCT refers to a procedure in which hematopoietic stem cells are infused to restore bone...

Engraftment syndrome (ES) is an early complication of hematopoietic stem cell transplantation (HSCT) that occurs around neutrophil engraftment time and is attributed to the sudden cytokine discharge associated with robust engraftment of transplanted cells. The secreted cytokines cause a clinical picture suggestive of an exaggerated inflammatory response. This complication has been described bot...

Cellular immunotherapy has proven to be effective in the treatment of hematological cancers by donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation and more recently by targeted therapy with chimeric antigen or T-cell receptor-engineered T cells. However, dependent on the tissue distribution of the antigens that are targeted, anti-tumor responses can be accompanied...